| Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells L Skalniak, KM Zak, K Guzik, K Magiera, B Musielak, M Pachota, ... Oncotarget 8 (42), 72167, 2017 | 256 | 2017 |
| Bioactive macrocyclic inhibitors of the PD‐1/PD‐L1 immune checkpoint K Magiera‐Mularz, L Skalniak, KM Zak, B Musielak, E Rudzinska‐Szostak, ... Angewandte Chemie International Edition 56 (44), 13732-13735, 2017 | 162 | 2017 |
| CA-170–a potent small-molecule PD-L1 inhibitor or not? B Musielak, J Kocik, L Skalniak, K Magiera-Mularz, D Sala, M Czub, ... Molecules 24 (15), 2804, 2019 | 123 | 2019 |
| Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint M Konieczny, B Musielak, J Kocik, L Skalniak, D Sala, M Czub, ... Journal of medicinal chemistry 63 (19), 11271-11285, 2020 | 55 | 2020 |
| Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells L Skalniak, J Kocik, J Polak, A Skalniak, M Rak, A Wolnicka-Glubisz, ... Cancers 10 (11), 396, 2018 | 54 | 2018 |
| Terphenyl-based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein− Protein Interaction D Muszak, E Surmiak, J Plewka, K Magiera-Mularz, J Kocik, B Musielak, ... | 48 | 2021 |
| Human and mouse PD-L1: similar molecular structure, but different druggability profiles K Magiera-Mularz, J Kocik, B Musielak, J Plewka, D Sala, M Machula, ... iScience, 101960, 2020 | 48 | 2020 |
| Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists J Kocik, M Machula, A Wisniewska, E Surmiak, TA Holak, L Skalniak Cancers 11 (7), 1014, 2019 | 35 | 2019 |
| PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action E Surmiak, K Magiera-Mularz, B Musielak, D Muszak, J Kocik-Krol, R Kitel, ... International Journal of Molecular Sciences 22 (21), 11797, 2021 | 22 | 2021 |
| Macrocyclic Peptide Inhibitor of PD‐1/PD‐L1 Immune Checkpoint K Magiera‐Mularz, K Kuska, L Skalniak, P Grudnik, B Musielak, J Plewka, ... Advanced Therapeutics, 2000195, 0 | 11 | |
| Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors MA Ważyńska, R Butera, M Requesens, A Plat, T Zarganes-Tzitzikas, ... Journal of Medicinal Chemistry, 2023 | 6 | 2023 |
| Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction S Shaabani, L Gadina, E Surmiak, Z Wang, B Zhang, R Butera, ... Molecules 27 (11), 3454, 2022 | 6 | 2022 |
| Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies I Rodriguez, J Kocik-Krol, L Skalniak, B Musielak, A Wisniewska, ... Molecular Cancer 22 (1), 1-8, 2023 | 2 | 2023 |
| Solubilizer tag effect on PD-L1/inhibitor binding properties for m-terphenyl derivatives E Surmiak, J Ząber, J Plewka, G Wojtanowicz, J Kocik-Krol, O Kruc, ... | 2 | 2023 |
| Characterization of bioactivity of PD-1/PD-L1 interaction inhibitors using classical and new in vitro models J Kocik-Król | | 2023 |
| Wpływ peptydów kininowych na regulację procesów oksydacyjno-redukcyjnych w chorobach nowotworowych M Biela, J Kocik, A Niewiarowska-Sendo Kraków: Creativetime, 2017 | | 2017 |
